The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Switching to aromatase inhibitor (AI) after tamoxifen in premenopausal patients with chemotherapy-induced amenorrhea (CIA) after early breast cancer treatment.
J. A. Perez-Fidalgo
Research Funding - Pfizer
Other Remuneration - Pfizer
M. J. Miranda
No relevant relationships to disclose
B. Bermejo
No relevant relationships to disclose
V. Pons
No relevant relationships to disclose
S. Rosello
No relevant relationships to disclose
E. Garcia-Garre
No relevant relationships to disclose
C. Guzman
Employment or Leadership Position - Pfizer
A. Lluch
Honoraria - Novartis; Pfizer
Research Funding - Pfizer